Captopril
Brand names: Capoten
Captopril is a short-acting angiotensin-converting enzyme (ACE) inhibitor used in hypertension, heart failure, after myocardial infarction and in diabetic nephropathy.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits ACE, reducing the conversion of angiotensin I to angiotensin II and decreasing aldosterone secretion, producing vasodilatation and reduced sodium and water retention.
Prescribing in practice
- Contraindicated in pregnancy due to the risk of fetal toxicity from drugs acting on the renin-angiotensin system.
- Can cause hyperkalaemia, renal impairment and first-dose hypotension, with particular caution in volume depletion, renal artery stenosis and concomitant potassium-sparing agents.
- May cause a persistent dry cough and, rarely, angioedema, which requires immediate discontinuation.
Monitoring
Monitor blood pressure, renal function and serum potassium before and after starting treatment and following dose changes.
Counselling the patient
- Tell your prescriber immediately if you become pregnant, as this medicine must be stopped.
- Report any swelling of the face, lips or throat urgently, and mention a persistent dry cough.
Evidence & guidelines
ACE inhibitors including captopril improve outcomes in heart failure and after myocardial infarction, as shown in landmark trials such as SAVE.
Reference: SmPC Capoten; NICE NG136 (Hypertension); NICE NG106 (Chronic HF); SAVE trial NEJM 1992; 327:669-77; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines